Table 2.
Relative risk of adverse outcomes for clinical trials included in the meta-analysis
| Adverse outcome (grade ≥3) | Trials (n) | No of patients (n)
|
Incidence, % (95%)
|
I2 | Relative risk (95%) | P-value | ||
|---|---|---|---|---|---|---|---|---|
| Bevacizumab, events/total | Controls, events/total | Bevacizumab | Controls | |||||
| ATEs | 4 | 32/1,079 | 16/877 | 2.6 (0.8%–7.9%) | 1.0 (0.2%–5.6%) | 78.3 | 2.83 (0.32–25.45) | 0.35 |
| VTEs | 7 | 58/1,919 | 30/1,470 | 1.6 (0.5%–4.5%) | 1.8 (0.6%–5.6%) | 14.0 | 0.98 (0.64–1.51) | 0.92 |
| GI perforation | 2 | 2/799 | 2/461 | 0.3 (0.1%–1.5%) | 0.6 (0.2%–1.9%) | 30.9 | 0.60 (0.09–4.10) | 0.60 |
| Hypertension | 8 | 162/1,870 | 22/1,428 | 8.2 (3.5%–17.8%) | 1.7 (0.7%–4.2%) | 0 | 5.34 (3.49–8.16) | <0.001 |
| Proteinuria | 6 | 32/1,491 | 0/1,083 | 2.5 (1.2%–5.3%) | 0 | 0 | 7.55 (2.26–25.22) | 0.001 |
| Hemorrhagic events | 9 | 72/2,051 | 17/1,607 | 3.6 (2.5%–5.0%) | 1.4 (0.9%–2.2%) | 0 | 2.61 (1.57–4.35) | <0.001 |
| Fatal adverse events | 8 | 89/1,977 | 51/1,530 | 4.6 (3.1%–6.7%) | 2.5 (1.2%–5.2%) | 43.9 | 1.21 (0.85–1.73) | 0.29 |
Note: I2≥50% suggests high heterogeneity across studies.
Abbreviations: ATEs, arterial thromboembolic events; VTEs, venous thromboembolic events; GI, gastrointestinal.